Medicines first developed to improve blood sugar control have quickly changed the treatment of obesity.
Now scientists are finding that GLP-1 drugs may affect far more than body weight, with possible benefits ranging from heart health to inflammation and even addictive behavior.
Dr. Steven Heymsfield of LSU’s Pennington Biomedical Research Center and Dr. Adam Gilden of the University of Colorado reviewed these unexpected effects in a new editorial. Their article, “Unanticipated Effects of GLP-1 Receptor Agonists: A Net Positive,” was published in the journal Obesity.
GLP-1 receptor agonists copy some of the actions of a natural hormone released after eating. They help control blood sugar, slow the movement of food through the stomach, and reduce hunger, which can lead people to eat less and lose substantial amounts of weight.
Newer medicines can act on more than one hormone system. These so-called dual agonists can produce even greater weight loss in some patients and have expanded the range of treatments available for obesity and related health problems.
The rapid growth of these medicines has given researchers a chance to see effects that were not obvious when the drugs were first developed. Heymsfield and Gilden wrote that many of these unexpected effects appear to be beneficial.
One area receiving attention is inflammation. Long-lasting inflammation is linked to many chronic diseases, including heart disease, diabetes, and some problems involving joints and other tissues.
Evidence suggests GLP-1 medicines may reduce certain signs of inflammation. Scientists are still working out whether this happens mainly because people lose weight or whether the drugs also have direct effects on cells and organs.
Researchers have also reported benefits involving the heart and blood vessels. Some GLP-1 medicines have already been shown in major clinical trials to lower the risk of serious heart problems in certain people with diabetes or obesity.
Possible benefits may extend to muscles, joints, and movement-related conditions as well. Losing excess weight can reduce pressure on joints, but researchers are studying whether other effects of the medicines may also contribute.
Another unexpected area involves alcohol and other addictive substances. Early studies suggest that some people taking GLP-1 medicines may drink less alcohol or experience changes in cravings.
These observations have created excitement about whether the drugs might eventually help treat alcohol use disorder or other substance use problems. However, the authors stress that larger and carefully controlled trials are needed before these medicines can be recommended for that purpose.
The drugs also raise important questions about muscle. When people lose a large amount of weight, they usually lose not only fat but also some lean tissue, which includes muscle.
Preserving muscle is especially important because muscle supports strength, movement, balance, and healthy aging. Researchers want better information about how much muscle people lose while taking GLP-1 drugs and how exercise, protein, and other nutritional strategies might reduce that loss.
Nutrition is another concern because these medicines can strongly reduce appetite. If people eat much less food, they may also consume fewer vitamins, minerals, protein, and other nutrients unless their diet is planned carefully.
The authors therefore argue that future research should look beyond the number on the scale. Scientists need to understand how these medicines change inflammation, body composition, eating patterns, and behavior over months or years.
The editorial also calls for randomized clinical trials examining lean body mass and ways to protect muscle. Larger trials are needed to test whether the apparent reduction in alcohol use is a true drug effect and whether it is large enough to help patients.
Overall, Heymsfield and Gilden conclude that current evidence points to a favorable balance between benefits and risks. GLP-1 and dual-agonist medicines have already changed medical care, and their influence is likely to grow as new drugs become available.
The editorial is useful because it looks beyond the well-known effects on weight and blood sugar and identifies questions that have emerged only after widespread use. Its main message is encouraging, but many of the extra benefits remain less firmly proven than the drugs’ effects on weight.
It is also important to separate promising observations from established treatments. Reduced inflammation and lower alcohol intake could become major additional benefits, but strong randomized studies are needed to show whether the medicines themselves cause these changes.
The biggest practical lesson may be that successful weight loss should not be judged by kilograms alone. As GLP-1 drugs reach more people, protecting muscle, maintaining good nutrition, and understanding their wider effects will become increasingly important parts of safe long-term treatment.
If you care about weight loss, please read studies that avocado could help you lose weight and belly fat, and a keto diet for weight loss can cause flu-like symptoms.
For more health information, please see recent studies about unhealthy plant-based diets linked to metabolic syndrome, and these antioxidants could help reduce dementia risk.
